Marcos Avila-Rodriguez

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9389537/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Sex differences in Parkinson's disease: Features on clinical symptoms, treatment outcome, sexual hormones and genetics. Frontiers in Neuroendocrinology, 2018, 50, 18-30.	2.5	106
2	Regulation of astroglia by gonadal steroid hormones under physiological and pathological conditions. Progress in Neurobiology, 2016, 144, 5-26.	2.8	101
3	Sleep Disorders Associated With Alzheimer's Disease: A Perspective. Frontiers in Neuroscience, 2018, 12, 330.	1.4	99
4	Alterations in Glucose Metabolism on Cognition: A Possible Link Between Diabetes and Dementia. Current Pharmaceutical Design, 2016, 22, 812-818.	0.9	60
5	Tibolone protects astrocytic cells from glucose deprivation through a mechanism involving estrogen receptor beta and the upregulation of neuroglobin expression. Molecular and Cellular Endocrinology, 2016, 433, 35-46.	1.6	60
6	Tibolone Reduces Oxidative Damage and Inflammation in Microglia Stimulated with Palmitic Acid through Mechanisms Involving Estrogen Receptor Beta. Molecular Neurobiology, 2018, 55, 5462-5477.	1.9	52
7	Alzheimer's Disease – Future Therapy Based on Dendrimers. Current Neuropharmacology, 2019, 17, 288-294.	1.4	42
8	Nanotechnology for Alzheimer Disease. Current Alzheimer Research, 2017, 14, 1182-1189.	0.7	41
9	Neurophysiology and Psychopathology Underlying PTSD and Recent Insights into the PTSD Therapies—A Comprehensive Review. Journal of Clinical Medicine, 2020, 9, 2951.	1.0	40
10	L-Type Calcium Channels Modulation by Estradiol. Molecular Neurobiology, 2017, 54, 4996-5007.	1.9	38
11	Medicinal Plants as Protective Strategies Against Parkinson's Disease. Current Pharmaceutical Design, 2017, 23, 4180-4188.	0.9	37
12	Can miRNAs Be Considered as Diagnostic and Therapeutic Molecules in Ischemic Stroke Pathogenesis?—Current Status. International Journal of Molecular Sciences, 2020, 21, 6728.	1.8	35
13	Targeting the Nicotinic Acetylcholine Receptors (nAChRs) in Astrocytes as a Potential Therapeutic Target in Parkinson's Disease. Current Pharmaceutical Design, 2016, 22, 1305-1311.	0.9	35
14	Role of neuroinflammation and sex hormones in war-related PTSD. Molecular and Cellular Endocrinology, 2016, 434, 266-277.	1.6	33
15	Growth Factors and Astrocytes Metabolism: Possible Roles for Platelet Derived Growth Factor. Medicinal Chemistry, 2016, 12, 204-210.	0.7	32
16	Neuroprotective effects of the catalytic subunit of telomerase: A potential therapeutic target in the central nervous system. Ageing Research Reviews, 2016, 28, 37-45.	5.0	29
17	ls VEGF a Key Target of Cotinine and Other Potential Therapies Against Alzheimer Disease?. Current Alzheimer Research, 2017, 14, 1155-1163.	0.7	28
18	Nicotine-Derived Compounds as Therapeutic Tools Against Post-Traumatic Stress Disorder. Current Pharmaceutical Design, 2015, 21, 3589-3595.	0.9	23

#	Article	IF	CITATIONS
19	Mitochondrial Permeability Transition Pore as a Suitable Targ e t for Neuroprotective Agents Against Alzheimer's Disease. CNS and Neurological Disorders - Drug Targets, 2017, 16, 677-685.	0.8	18
20	Novel Approaches in Astrocyte Protection: from Experimental Methods to Computational Approaches. Journal of Molecular Neuroscience, 2016, 58, 483-492.	1.1	15
21	Advances in Medicinal Plants with Effects on Anxiety Behavior Associated to Mental and Health Conditions. Current Medicinal Chemistry, 2017, 24, 411-423.	1.2	14
22	Approaches for the Development of Drugs for Treatment of Obesity and Metabolic Syndrome. Current Pharmaceutical Design, 2016, 22, 895-903.	0.9	14
23	Application of Acyzol in the Context of Zinc Deficiency and Perspectives. International Journal of Molecular Sciences, 2019, 20, 2104.	1.8	13
24	The Effect of Short-Term Physical Activity on the Oxidative Stress in Rats with Different Stress Resistance Profiles in Cerebral Hypoperfusion. Molecular Neurobiology, 2020, 57, 3014-3026.	1.9	12
25	Microglial dependent protective effects of neuroactive steroids. CNS and Neurological Disorders - Drug Targets, 2016, 15, 242-249.	0.8	12
26	Comparing the Treatment of Congenital Spine Deformity Using Freehand Techniques In Vivo and 3D-Printed Templates In Vitro (Prospective–Retrospective Single-Center Analytical Single-Cohort) Tj ETQq0 0 () rgB∃ /Ov	erlæck 10 Tf 5
27	Cerebrospinal Fluid, Brain Electrolytes Balance, and the Unsuspected Intrinsic Property of Melanin to Dissociate the Water Molecule. CNS and Neurological Disorders - Drug Targets, 2018, 17, 743-756.	0.8	8
28	The Use of Fibrin-based Tissue Adhesives for Breast in Reconstructive and Plastic Surgery. Current Topics in Medicinal Chemistry, 2020, 19, 2985-2990.	1.0	6
29	Copper and Neurotoxicity in Autism Spectrum Disorder. Current Pharmaceutical Design, 2020, 25, 4747-4754.	0.9	5
30	The Posterior Perforated Substance: A Brain Mystery Wrapped in an Enigma. Current Topics in Medicinal Chemistry, 2020, 19, 2991-2998.	1.0	5
31	Classification (Agonist/Antagonist) and Regression "Structure-Activity―Models of Drug Interaction with 5-HT6. Central Nervous System Agents in Medicinal Chemistry, 2018, 18, 213-221.	0.5	4
32	Cytotoxic Effects of Blue Scorpion Venom (Rhopalurus junceus) in a Glioblastoma Cell Line Model. Current Pharmaceutical Biotechnology, 2021, 22, 636-645.	0.9	4
33	Recent Reports on Redox Stress-Induced Mitochondrial DNA Variations, Neuroglial Interactions, and NMDA Receptor System in Pathophysiology of Schizophrenia. Molecular Neurobiology, 2022, 59, 2472-2496.	1.9	4
34	Synthesis and Cytotoxic Activity of Azine Derivatives of 6-Hydroxyxanthanodiene. Current Cancer Drug Targets, 2020, 20, 666-674.	0.8	3
35	Natural Antioxidants in Dementia. , 2015, , 827-836.		2
36	A Novel Heterocyclic System Based on Natural Epoxyalantolactone. Frontiers in Chemistry, 2019, 7, 655.	1.8	1

#	Article	IF	CITATIONS
37	Statistical Review of the Suicide Attempts Rates Committed on Polish Railway Tracks between the Years 2013-2016. Central Nervous System Agents in Medicinal Chemistry, 2021, 21, 85-92.	0.5	1
38	New Insights into Oxidative Damage and Iron Associated Impairment in Traumatic Brain Injury. Current Pharmaceutical Design, 2020, 25, 4737-4746.	0.9	1